Zoetis Lags Peers as Analysts Trim and Q3 Looms

ZTS slipped 1.6% on the week to $79.72, a notably weaker outcome than its closest peers: PAHC was flat, PBH added 2.6%, and SAN gained 7.6% over the same period.

The analyst desk has been active and mostly cautious. Morgan Stanley kept its Overweight rating but trimmed its target to $82 from $85 on October 29, landing it within arm's reach of where the stock already trades. That compression matters: an Overweight call with only $2 of implied upside carries far less weight than one with a meaningful cushion. UBS moved the other way, nudging its Neutral target up to $85 from $80 on October 27. BTIG suspended coverage entirely on October 30. The Jefferies downgrade to Hold and Goldman's Neutral initiation at $74, both from mid-October, remain on the tape. The consensus is now three buys against eleven holds, with a mean target of $88.38. Goldman's floor at $74 sits below the current price. The spread from $74 to the remaining buy targets captures the disagreement about where the animal health cycle is headed.

Borrow conditions offer no particular drama. Short interest has edged up about 4.8% over the week to roughly 4.1% of the free float, a modest level that does not point to a crowded short. Cost to borrow has risen sharply in percentage terms, up 139% on the week, but the absolute level remains low at 0.41%. Availability is extremely loose at over 3,000%, meaning there is far more capacity in the lending pool than shares currently borrowed. Options positioning is equally benign. The put/call ratio of 0.46 is marginally below its 20-day average and well within normal range, nowhere near the defensive extremes seen when the PCR hit 0.67 earlier in the year. Taken together, the lending market and options market are not flashing stress.

The valuation picture reflects a stock that has re-rated sharply lower. The price-to-earnings multiple has expanded modestly over 30 days as the stock recovered from its year-to-date lows, but the earnings yield factor ranks in the 92nd percentile of the ORTEX universe, meaning the stock looks cheap relative to earnings on a historical basis. EPS momentum over both 30 and 90 days ranks in the low 20s to low 30s out of 100, reflecting the string of downward estimate revisions that has followed each quarterly print. Retail attention is worth noting: the Wikipedia views dataset is running at a z-score of 2.1 against Zoetis's own 90-day history, its highest attention reading in recent months, likely driven by the earnings event approaching on November 3.

The most recent quarterly prints give a sense of how the stock has responded. Q2 results in August produced a 2.3% drop on the day, which then reversed into a 1.9% gain over the following five days. The prior quarter saw the opposite pattern, a 1.6% gain on day one followed by a 3.3% fade over the week. Neither reaction was dramatic by pharmaceutical standards, but the pattern of initial volatility followed by mean reversion is worth holding in mind as the Q3 number arrives.

The level to watch is Morgan Stanley's $82 target, which sits just above the current price and effectively marks the point where one of the few remaining bullish-rated desks would have little argument left for adding.